arrow_back Back to App

Affordable Prescriptions Act: Prohibiting Product Hopping

This bill amends the Federal Trade Commission Act to prohibit "product hopping." This practice involves withdrawing a reference drug or making changes that impede competition from generic and biosimilar drugs.
Key points
Defines and prohibits "hard" and "soft" switches by manufacturers that impede competition from generic or biosimilar alternatives.
Authorizes the Federal Trade Commission (FTC) to seek equitable remedies, including disgorgement of unjust enrichment and restitution, from violators.
Limits the number of patents (to 20) that a reference product sponsor can assert in infringement actions against biosimilar applicants.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_1435
Sponsor: Sen. Cornyn, John [R-TX]
Process start date: 2021-04-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-3-pro-preview
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Affordable Prescriptions for Patients Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_1435.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • Defines and prohibits "hard" and "soft" switches by manufacturers that impede competition from generic or biosimilar alternatives.
  • Authorizes the Federal Trade Commission (FTC) to seek equitable remedies, including disgorgement of unjust enrichment and restitution, from violators.
  • Limits the number of patents (to 20) that a reference product sponsor can assert in infringement actions against biosimilar applicants.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Cornyn, John [R-TX].

What is the latest detailed status?

The latest detailed status is: Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

CATEGORIES

Health Courts and Law Economy